Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy

Vasc Health Risk Manag. 2010 Nov 24:6:1065-75. doi: 10.2147/VHRM.S14053.

Abstract

Objective: To compare the effects of combination niacin extended-release + simvastatin (NER/S) versus atorvastatin alone on apolipoproteins and lipid fractions in a post hoc analysis from SUPREME, a study which compared the lipid effects of niacin extended-release + simvastatin and atorvastatin in patients with hyperlipidemia or mixed dyslipidemia.

Patients and methods: Patients (n = 137) with dyslipidemia (not previously receiving statin therapy or having discontinued any lipid-altering treatment 4-5 weeks prior to the study) received NER/S (1000/40 mg/day for four weeks, then 2000/40 mg/day for eight weeks) or atorvastatin 40 mg/day for 12 weeks. Median percent changes in apolipoprotein (apo) A-1, apo B, and the apo B:A-I ratio, and nuclear magnetic resonance lipoprotein subclasses from baseline to week 12 were compared using the Wilcoxon rank-sum test and Fisher's exact test.

Results: NER/S treatment produced significantly greater percent changes in apo A-I and apo B:A-I, and, at the final visit, apo B < 80 mg/dL was attained by 59% versus 33% of patients, compared with atorvastatin treatment (P = 0.003). NER/S treatment resulted in greater percent reductions in calculated particle numbers for low-density lipoprotein (LDL, 52% versus 43%; P = 0.022), small LDL (55% versus 45%; P = 0.011), very low-density lipoprotein (VLDL) and total chylomicrons (63% versus 39%; P < 0.001), and greater increases in particle size for LDL (2.7% versus 1.0%; P = 0.007) and VLDL (9.3% versus 0.1%; P < 0.001), compared with atorvastatin.

Conclusion: NER/S treatment significantly improved apo A-I levels and the apo B:A-I ratio, significantly lowered the number of atherogenic LDL particles and VLDL and chylomicron particles, and increased the mean size of LDL and VLDL particles, compared with atorvastatin.

Keywords: atorvastatin; diameter; dyslipidemia; lipid particles; niacin; number; simvastatin; size.

Publication types

  • Clinical Trial, Phase III
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anticholesteremic Agents / pharmacology
  • Anticholesteremic Agents / therapeutic use
  • Atherosclerosis / prevention & control*
  • Atorvastatin
  • Delayed-Action Preparations
  • Drug Therapy, Combination
  • Dyslipidemias / blood
  • Dyslipidemias / complications
  • Dyslipidemias / drug therapy*
  • Female
  • Heptanoic Acids / pharmacology
  • Heptanoic Acids / standards
  • Heptanoic Acids / therapeutic use*
  • Humans
  • Hyperlipidemias / complications
  • Hyperlipidemias / drug therapy
  • Hypolipidemic Agents / pharmacology
  • Hypolipidemic Agents / therapeutic use*
  • Lipoproteins / blood
  • Lipoproteins / drug effects
  • Magnetic Resonance Spectroscopy
  • Male
  • Middle Aged
  • Niacin / pharmacology
  • Niacin / standards
  • Niacin / therapeutic use*
  • Pyrroles / pharmacology
  • Pyrroles / standards
  • Pyrroles / therapeutic use*
  • Simvastatin / pharmacology
  • Simvastatin / standards
  • Simvastatin / therapeutic use*
  • Treatment Outcome
  • United States

Substances

  • Anticholesteremic Agents
  • Delayed-Action Preparations
  • Heptanoic Acids
  • Hypolipidemic Agents
  • Lipoproteins
  • Pyrroles
  • Niacin
  • Atorvastatin
  • Simvastatin